Gelicon300 mg

Gelicon 300 mg is used as a hypolipidemic agent in conjunction with dietary modification. It is recommended in the treatment of type IIa, type IIb, type III, type IV and type V hyperlipoproteinemia.

Dyslipidaemic Agents

Gelicon 300 mg is an anti-lipemic agent. Gelicon 300 mg decreases serum triglycerides in healthy individuals and patients with hyper-triglyceridemia. It decreases very low-density lipoprotein (VLDL)- triglyceride concentration and to a lesser extent, LDL triglyceride concentration. HDL-triglyceride is usually decreased slightly. Gelicon 300 mg usually increases the HDL-cholesterol fraction in healthy individuals and patients with hyperlipoproteinemia, an action that may be beneficial in slowing the progression of atherosclerosis and in reducing the risk of coronary heart disease.Gelicon 300 mg also inhibits synthesis of VLDL carrier apolipoprotein B, leading to a decrease in VLDL production. How Gelicon 300 mg raises HDL concentration is not known. Gelicon 300 mg inhibits lipolysis of fat in adipose tissue and decreases the hepatic uptake of plasma free fatty acids, thereby reducing hepatic triglyceride production.Gelicon 300 mg is rapidly and completely absorbed from the gastrointestinal tract. Peak concentration in plasma occurs within 1 to 2 hours; the half-life is about 1.5 hours. About 70% of a dose is excreted in the urine; little is excreted in the faeces.

The usual dose by mouth is 1.2 gm daily in 2 divided doses given 30 minutes before morning and evening meal. The dosage range may vary between 0.9-1.5 gm daily or as directed by the physician.

The usual dose by mouth is 1.2 gm daily in 2 divided doses given 30 minutes before morning and evening meal. The dosage range may vary between 0.9-1.5 gm daily or as directed by the physician.

Concomitant anticoagulant dosage may need to be reduced and frequent determinations of prothrombin carried out to confirm that the desired prothrombin level has been re-established. There have been reports of severe myositis with marked elevation of creatinine kinase and myoglobinuria when Gelicon 300 mg and lovastatin were used concomitantly. In most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefit of combined therapy with lovastatin and Gelicon 300 mg does not outweigh the risks of severe myopathy, rhabdomyolysis and acute renal failure.

It is contraindicated in case of alcoholism, hepatic impairment, gallstone, and pregnancy and to patients hypersensitive to Gelicon 300 mg.

The most frequent adverse effect involves the G. I. Tract. Abdominal pain and epigastric pain or dyspepsia is common adverse G. I. effects. Other adverse reaction includes pruritus, rash, headache, dizziness, blurred vision, painful extremities and rarely myalgia.

Safe use in human pregnancy has not been established. It is not known whether Gelicon 300 mg is secreted in human milk. Like most drugs, Gelicon 300 mg should normally be avoided during pregnancy and lactation.

Risk benefit must be considered in case of lactating mother. Before initiation long-term treatment lipid profile, blood counts, renal activity, annual eye examination and liver function tests should be done.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Dyslipidaemic Agents

Gelicon 300 mg is an anti-lipemic agent. Gelicon 300 mg decreases serum triglycerides in healthy individuals and patients with hyper-triglyceridemia. It decreases very low-density lipoprotein (VLDL)- triglyceride concentration and to a lesser extent, LDL triglyceride concentration. HDL-triglyceride is usually decreased slightly. Gelicon 300 mg usually increases the HDL-cholesterol fraction in healthy individuals and patients with hyperlipoproteinemia, an action that may be beneficial in slowing the progression of atherosclerosis and in reducing the risk of coronary heart disease.Gelicon 300 mg also inhibits synthesis of VLDL carrier apolipoprotein B, leading to a decrease in VLDL production. How Gelicon 300 mg raises HDL concentration is not known. Gelicon 300 mg inhibits lipolysis of fat in adipose tissue and decreases the hepatic uptake of plasma free fatty acids, thereby reducing hepatic triglyceride production.Gelicon 300 mg is rapidly and completely absorbed from the gastrointestinal tract. Peak concentration in plasma occurs within 1 to 2 hours; the half-life is about 1.5 hours. About 70% of a dose is excreted in the urine; little is excreted in the faeces.

Safe use in human pregnancy has not been established. It is not known whether Gelicon 300 mg is secreted in human milk. Like most drugs, Gelicon 300 mg should normally be avoided during pregnancy and lactation.